Vardenafil for the treatment of erectile dysfunction: A critical review of the literature based on personal clinical experience

European Urology

Volumn 47, Issue 5, 2005, Pages 612-621

  Montorsi, Francesco ^a   Salonia, Andrea ^a   Briganti, Alberto ^a   Barbieri, Luigi ^a   Zanni, Giuseppe ^a   Suardi, Nazareno ^a   Cestari, Andrea ^a   Montorsi, Piero ^b   Rigatti, Patrizio ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Erectile dysfunction; Phosphodiesterase type 5 inhibitors; Review; Vardenafil

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; CYTOCHROME P450 INHIBITOR; ERYTHROMYCIN; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; NITRATE; PHOSPHODIESTERASE V INHIBITOR; RITONAVIR; SILDENAFIL; TADALAFIL; TAMSULOSIN; VARDENAFIL;

AREA UNDER THE CURVE; ARTHRALGIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DEPRESSION; DIABETES MELLITUS; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG LABELING; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPEPSIA; ERECTILE DYSFUNCTION; EXPERIENCE; FLU LIKE SYNDROME; FLUSHING; HEADACHE; HEART INFARCTION; HUMAN; HYPOTENSION; INJURY; MAXIMUM PERMISSIBLE DOSE; MEDLINE; NAUSEA; NONHUMAN; PATIENT COUNSELING; PEER REVIEW; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATECTOMY; RELIABILITY; REVIEW; RHINITIS; SIDE EFFECT; SINUSITIS; VISUAL IMPAIRMENT;

EID: 17144376409     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2005.01.007     Document Type: Review

References (39)

1. I. Sáenz de Tejada, J. Angulo, P. Cuevas, A. Fernandez, I. Moncada, and A. Allona The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil Int J Impot Res 13 2001 282 290
2. E. Gbekor, S. Bethell, L. Fawcett, N. Mount, and S. Phillips Selectivity of sildenafil and other phosphodiesterase type 5 (PDE5) inhibitors against all human phosphodiesterase families Eur Urol 1 Suppl 1 2002 63
3. N.N. Kim, Y.H. Huang, I. Goldstein, E. Bischoff, and A.M. Trais Inhibition of cyclic GMP hydrolysis in human corpus cavernosum smooth muscle cells by vardenafil, a novel, selective phosphodiesterase type 5 inhibitor Life Sci 69 2001 2249 2256
4. T. Klotz, R. Sachse, A. Heidrich, F. Jockenhövel, G. Rohde, and G. Wensing Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study World J Urol 19 2001 32 39
5. S. Stark, R. Sachse, T. Liedl, J. Hensen, G. Rohde, and G. Wensing Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose Eur Urol 40 2001 181 188
6. P. Rajagopalan, A. Mazzu, C. Xia, R. Dawkins, and P. Sundaresan Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction J Clin Pharmacol 43 2003 260 267
7. T. Klotz, R.J. Bauer, and G. Rohde Effect of renal impairment on the single-dose pharmacokinetics of vardenafil 20 mg, a selective PDE5 inhibitor for the treatment of erectile dysfunction Pharmacotherapy 22 2002 418
8. http://www.emea.eu.int/humandocs/Humans/EPAR/levitra/levitra.htm
9. S. Auerbach, M. Gittelman, A. Mazzu, P. Sundaresan, and W. White Coadministered vardenafil for erectile dysfunction and tamsulosin do not induce hypotension in patients with benign prostatic hypertrophy Am J Hypertens 17 5 Suppl 1 2004 16A (abs OR35)
10. W.J.G. Hellstrom, M. Gittelman, G. Karlin, T. Segerson, M. Thibonnier, T. Taylor on behalf of the Vardenafil Study Group Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial J Androl 23 2002 763 771
11. I. Goldstein, J.M. Young, J. Fischer, K. Bangerter, T. Segerson, and T. Taylor Vardenafil, a new phosphodiesterase type 5 inhibitor in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study Diabetes Care 26 2003 777 783
12. H. Porst, R. Rosen, H. Padma-Nathan, I. Goldstein, F. Giuliano, and E. Ulbrich The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial Int J Impot Res 13 2001 192 199
13. C. Stief, H. Porst, S. de Tejada, E. Ulbrich, and M. Beneke Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction Int J Clin Pract 58 2004 230 239
14. G. Brock, A. Nehra, L.I. Lipshultz, G.S. Karlin, M. Gleave, and M. Seger Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy J Urol 170 2003 1278 1283
15. A.-J. Potempa, E. Ulbrich, I. Bernard, M. Beneke on behalf of the Vardenafil Study Group Efficacy of vardenafil in men with erectile dysfunction: A flexible dose community practice study Eur Urol 46 2004 73 79
16. D. Hatzichristou, F. Montorsi, J. Buvat, N. Laferriere, T. Bandel, and H. Porst The efficacy and safety of flexible-dose vardenafil (Levitra) in a broad population of European men Eur Urol 45 2004 634 641
17. Carson CC, Hatzichristou DG, Carrier S, Lording D, Lyngdorf P, Aliotta P, et al. for the PROVEN Study Group. Erectile response with vardenafil in sildenafil non-responders: A multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial. BJU Int 2004; in press.
18. R.C. Rosen, J.C. Cappelleri, and N. Gendrano IIIrd The International Index of Erectile Function (IIEF): a state-of-the-science review Int J Impot Res 14 2002 226 244
19. I. Goldstein, J. Young, T. Segerson, and M. Thibonnier Long-term efficacy and safety of vardenafil in diabetic men with erectile dysfunction Diabetes 51 Suppl 2 2002 A98
20. I. Saenz de Tejada, G. Anglin, J.R. Knight, and J.T. Emmick Effects of tadalafil on erectile dysfunction in men with diabetes Diabetes Care 25 2002 2159 2164
21. M.R. Safarinejad Oral sildenafil in the treatment of erectile dysfunction in diabetic men: a randomized double-blind and placebo-controlled study J Diabetes Complications 18 2004 205 210
22. J. Grantmyre, G. Brock, A. Nadel, and M. Seger Efficacy and tolerability of vardenafil in men with erectile dysfunction and residual tumescence following radical retropubic prostatectomy J Andrology SS 2004 58 (abstract 61)
23. H. Padma-Nathan, A.R. McCullough, F. Giuliano, S.M. Toler, and C. Wohlhuter Post-operative nightly administration of sildenafil citrate significantly improves the return of normal spontaneous erectile function after bilateral nerve-sparing radical prostatectomy J Urol 4 Suppl 2003 169 abstract 1402
24. R. Rosen, F. Montorsi, P. Assalian, L. Rodriguez-Vela, R. Porto, and K. Bangerter Efficacy and tolerability of vardenafil in men with mild major depressive disorder and erectile dysfunction: the Depression Related Improvement with Vardenafil for Erectile Response (DRIVER) study Eur Urol 3 2004 235 (LB14)
25. A. Shabsigh, R. Porto, and I. Goldstein Time course of erectile function and depression intensity improvement in men with mild major depressive disorder and erectile dysfunction after treatment with vardenafil Sexual and Relationship Therapy 19 Suppl 1 2004 S67 (abstract 326)
26. H. Padma-Nathan, J. Kaufman, and T. Taylor Earliest time of onset of erections with vardenafil determined in an at-home setting J Androl 24 2003 48 (abstract 41)
27. F. Montorsi, H. Padma-Nathan, J. Buvat, H. Schwaibold, M. Beneke, E. Ulbrich for the Vardenafil Study Group Earliest time to onset of action leading to successful intercourse with vardenafil determined in an at-home setting: A randomised, double-blind, placebo-controlled trial J Sex Med 1 2004 168 178
28. E. Bischoff Vardenafil preclinical trial data: Potency, pharmacodynamics, pharmacokinetics and adverse events Int J Impot Res 16 Suppl 1 2004 S34 S37
29. M.A. Blount, A. Beasley, R. Zoraghi, K.R. Sekhar, E.P. Bessay, and S.H. Francis Binding of titrated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation Mol Pharmacol 66 2004 144 152
30. Stief C, Valiquette L, Montorsi F, Hellstrom W, Giuliano F, Homering M, et al. Vardenafil (Levitra®) improves maintenance success rates from within 15 minutes to up to 12 hours from time of dosing to start of sexual activity. Poster presented at the World Congress on the Aging Male, Prague, Czech Republic, February 26-29, 2004.
31. J.M. Young Vardenafil Expert Opin Investig Drugs 11 2002 1487 1496
32. R. Kloner, P. Mohan, T. Segerson, M. Thibonnier, C. Norenberg, and H. Padma-Nathan Cardiovascular safety of vardenafil in patients receiving antihypertensive medications: a post-hoc analysis of five placebo-controlled clinical trials J Am Coll Cardiol 41 2003 276A (A-120)
33. R.A. Kloner, H. Porst, P. Mohan, C. Norenberg, K. Pomerantz, and T. Segerson Cardiovascular safety of the selective PDE5 inhibitor vardenafil in patients with erectile dysfunction: an analysis of five placebo-controlled clinical trials Int J Impot Res 14 Suppl 4 2002 S22
34. U. Thadani, W. Smith, S. Nash, N. Bittar, S. Glasser, and P. Narayan The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease J Am Coll Cardiol 40 2002 2006 2012
35. U. Thadani, A. Mazzu and the Vardenafil Study Group The effect of 20 mg Levitra (vardenafil) on ischemic threshold, exercise tolerance, and circulatory responses during treadmill exercise in men with stable angina pectoris Can J Cardiol 19 Suppl A 2003 252A
36. J. Morganroth, B.E. Ilson, B.C. Shaddinger, G.A. Dabiri, B.R. Patel, and D.A. Boyle Evaluation of vardenafil and sildenafil on cardiac repolarization Am J Cardiol 93 2004 1378 1383
37. P. Montorsi, T. Roumeguere, F. Montorsi, P.M. Ravagnani, S. Galli, and A. Briganti Is there a link between erectile dysfunction and ischemic heart disease? EAU Update Series 2 2 2004 43 48
38. F. Montorsi, and A. Salonia Editorial Comment EAU Update Series 2 2 2004 41 42
39. R. DeBusk, U. Drory, and I. Goldstein Management of sexual dysfunction in patients with cardiovascular disease: Recommendations of the Princeton Consensus Panel Am J Cardiol 86 2000 175 181